79 related articles for article (PubMed ID: 1981983)
1. [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
Cheymol G
Bull Acad Natl Med; 1990 Oct; 174(7):959-67; discussion 967-8. PubMed ID: 1981983
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Cheymol G; Poirier JM; Carrupt PA; Testa B; Weissenburger J; Levron JC; Snoeck E
Br J Clin Pharmacol; 1997 Jun; 43(6):563-70. PubMed ID: 9205815
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R
Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.
Le Jeunne C; Poirier JM; Cheymol G; Ertzbischoff O; Engel F; Hugues FC
Eur J Clin Pharmacol; 1991; 41(2):171-4. PubMed ID: 1683835
[TBL] [Abstract][Full Text] [Related]
5. Comparison of propranolol and sotalol pharmacokinetics in obese subjects.
Poirier JM; Le Jeunne C; Cheymol G; Cohen A; Barré J; Hugues FC
J Pharm Pharmacol; 1990 May; 42(5):344-8. PubMed ID: 1976782
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic comparison of propranolol and atenolol in people with primary hypertension].
Telatyńska-Smieszek B
Ann Acad Med Stetin; 2002; 48():367-80. PubMed ID: 14601489
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
Cheymol G; Weissenburger J; Poirier JM; Gellee C
Br J Clin Pharmacol; 1995 Jun; 39(6):684-7. PubMed ID: 7654489
[TBL] [Abstract][Full Text] [Related]
8. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol.
Rey E; Jammet P; d'Athis P; de Lauture D; Christoforov B; Weber S; Olive G
Arzneimittelforschung; 1987 Aug; 37(8):953-6. PubMed ID: 2890358
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance.
Borchard U
Clin Physiol Biochem; 1990; 8 Suppl 2():28-34. PubMed ID: 1982759
[TBL] [Abstract][Full Text] [Related]
10. [Consumption of antihypertensive agents in obese patients: a cross-sectional study in a sample of 3,291 wage-earners in the Toulous region].
Lapeyre-Mestre M; Sulem P; Chastan E; Niezborala M; Briant D; Jansou P; Sanguignol F; Montastruc JL
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):925-9. PubMed ID: 10989731
[TBL] [Abstract][Full Text] [Related]
11. Cimetidine disposition in obesity.
Abernethy DR; Greenblatt DJ; Matlis R; Gugler R
Am J Gastroenterol; 1984 Feb; 79(2):91-4. PubMed ID: 6364798
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.
Dvorchik BH; Damphousse D
J Clin Pharmacol; 2005 Jan; 45(1):48-56. PubMed ID: 15601805
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic changes in obesity].
Girardin E; Bruguerolle B
Therapie; 1993; 48(4):397-402. PubMed ID: 8128423
[TBL] [Abstract][Full Text] [Related]
14. [Tissue distribution of 3 beta-blockers in dogs].
Bouquet S; Quehen S; Saux MC; Joire JE; Courtois P; Fourtillan JB
Ann Pharm Fr; 1987; 45(3):205-13. PubMed ID: 2893573
[No Abstract] [Full Text] [Related]
15. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.
Cheymol G; Woestenborghs R; Snoeck E; Ianucci R; Le Moing JP; Naditch L; Levron JC; Poirier JM
Eur J Clin Pharmacol; 1997; 51(6):493-8. PubMed ID: 9112066
[TBL] [Abstract][Full Text] [Related]
16. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
Mehvar R; Brocks DR
J Pharm Pharm Sci; 2001; 4(2):185-200. PubMed ID: 11466176
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of drugs in obesity. An update.
Cheymol G
Clin Pharmacokinet; 1993 Aug; 25(2):103-14. PubMed ID: 8403734
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia.
Telatyńska B; Wójcicki J; Droździk M; Gawrońska-Szklarz B; Sulzyc-Bielicka V; Sterna R
Pol J Pharmacol; 2003; 55(1):81-9. PubMed ID: 12856830
[TBL] [Abstract][Full Text] [Related]
19. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen.
Abernethy DR; Greenblatt DJ; Divoll M; Shader RI
J Lab Clin Med; 1983 Jun; 101(6):873-80. PubMed ID: 6133901
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol.
Plewan A; Lehmann G; Ndrepepa G; Schreieck J; Alt EU; Schömig A; Schmitt C
Eur Heart J; 2001 Aug; 22(16):1504-10. PubMed ID: 11482924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
